Dalteparin for VTE Prophylaxis in Obese Patients
Enoxaparin for VTE Prophylaxis in Obese Patients
Unfractionated Heparin for VTE Prophylaxis in Obese Patients
Fondaparinux for VTE Prophylaxis in Obese Patients
SallahSWanJYNguyenNP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost2002;87:575–579.
KhoranaAADalalMLinJConnollyGC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer2013;119:648–655.
CohenATTapsonVFBergmannJF. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet2008;371:387–394.
TapsonVFDecoususHPiniM. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest2007;132:936–945.
ChewHKWunTHarveyD. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med2006;166:458–464.
ChewHKWunTHarveyDJ. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol2007;25:70–76.
KudererNMFrancisCWCulakovaE. Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy [abstract]. J Clin Oncol2008;26(Suppl 15):Abstract 9521.
MartinoMAWilliamsonESiegfriedS. Diagnosing pulmonary embolism: experience with spiral CT pulmonary angiography in gynecologic oncology. Gynecol Oncol2005;98:289–293.
NgMFlemingTRobinsonM. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet2014;384:766–781.
KeumNGreenwoodDCLeeDH. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst2015;107.
RenehanAGTysonMEggerM. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet2008;371:569–578.
ArnoldMPandeyaNByrnesG. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol2015;16:36–46.
World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report. Food Nutrition Physical Activity and the Prevention of Ovarian Cancer 2014: AICR; 2014. Available at: http://www.dietandcancerreport.org/cup/cup_resources.php. Accessed August 23 2015.
World Cancer Research Fund/American Institute for Cancer Research. Food Nutrition Physical Activity and the Prevention of Cancer: a Global Perspective. Washington DC: AICR; 2007. Available at: http://www.dietandcancerreport.org/cancer_resource_center/er_full_report_english.php. Accessed August 23 2015.
CUP team Imperial College London. Continuous update of the epidemiological evidence on food nutrition physical activity and the risk of gallbladder cancer: AICR; 2012. Available at: http://www.dietandcancerreport.org/cancer_resource_center/downloads/cu/CUP_gallbladder_cancer_protocol.pdf. Accessed August 23 2015.
GolabekTBukowczanJChlostaP. Obesity and prostate cancer incidence and mortality: a systematic review of prospective cohort studies. Urol Int2014;92:7–14.
ChenYWangXWangJ. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer2012;48:2137–2145.
DobbinsMDecorbyKChoiBC. The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med2013;2013:680536.
CastilloJJInghamRRReaganJL. Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studies. Clin Lymphoma Myeloma Leuk2014;14:122–130.
LarssonSCWolkA. Body mass index and risk of non-Hodgkin's and Hodgkin's lymphoma: a meta-analysis of prospective studies. Eur J Cancer2011;47:2422–2430.
KitaharaCMPlatzEAFreemanLE. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev2011;20:464–472.
BlomJWDoggenCJOsantoSRosendaalFR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA2005;293:715–722.
HeitJAO'FallonWMPettersonTM. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med2002;162:1245–1248.
KhoranaAAKudererNMCulakovaE. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood2008;111:4902–4907.
OlsonNCCushmanMJuddSE. American Heart Association's Life's Simple 7 and risk of venous thromboembolism: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. J Am Heart Assoc2015;4:e001494.
KlovaiteJBennMNordestgaardBG. Obesity as a causal risk factor for deep venous thrombosis: a Mendelian randomization study. J Intern Med2015;277:573–584.
WattanakitKLutseyPLBellEJ. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost2012;108:508–515.
OlsonNCCushmanMLutseyPL. Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. J Thromb Haemost2014;12:1993–2001.
WattsJLKuehnlenzDSuloS. Common characteristics of patients diagnosed with upper-extremity venous thromboembolism during hospitalization: a descriptive study. Clin Nurse Spec2015;29:48–54.
HansenJBFernandezJABorchKH. Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism. Thromb Res2012;129:502–507.
HicksLKCheungMCDingK. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer2009;115:5516–5525.
TsaiJGrantAMBeckmanMG. Determinants of venous thromboembolism among hospitalizations of US adults: a multilevel analysis. PLoS One2015;10:e0123842.
WuXSWuWGLiML. Impact of being overweight on the surgical outcomes of patients with gastric cancer: a meta-analysis. World J Gastroenterol2013;19:4596–4606.
ChildsBRNahmNJDolencAJVallierHA. Obesity is associated with more complications and longer hospital stays after orthopaedic trauma[published online ahead of print March 9 2015]. J Orthop Traumain press.
SiHBZengYShenB. The influence of body mass index on the outcomes of primary total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc2015;23:1824–1832.
DayJSRamseyMLLauEWilliamsGR. Risk of venous thromboembolism after shoulder arthroplasty in the Medicare population. J Shoulder Elbow Surg2015;24:98–105.
ParviziJHuangRRaphaelIJ. Symptomatic pulmonary embolus after joint arthroplasty: stratification of risk factors. Clin Orthop Relat Res2014;472:903–912.
HaskinsINAmdurRSaraniBVaziriK. Congestive heart failure is a risk factor for venous thromboembolism in bariatric surgery[published online ahead of print December 24 2014]. Surg Obes Relat Dis.doi: 10.1016/j.soard.2014.12.020.
JamalMHCorcellesRShimizuH. Thromboembolic events in bariatric surgery: a large multi-institutional referral center experience. Surg Endosc2015;29:376–380.
ChanMMHamzaNAmmoriBJ. Duration of surgery independently influences risk of venous thromboembolism after laparoscopic bariatric surgery. Surg Obes Relat Dis2013;9:88–93.
RobinsonKAO'DonnellMEPearsonD. Portomesenteric venous thrombosis following major colon and rectal surgery: incidence and risk factors. Surg Endosc2015;29:1071–1079.
LiuYGaoYWeiL. Peripherally inserted central catheter thrombosis incidence and risk factors in cancer patients: a double-center prospective investigation. Ther Clin Risk Manag2015;11:153–160.
LeungAHealCPereraMPretoriusC. A systematic review of patient-related risk factors for catheter-related thrombosis. J Thromb Thrombolysis2015;40:363–373.
BlaivasMStefanidisKNanasS. Sonographic and clinical features of upper extremity deep venous thrombosis in critical care patients. Crit Care Res Pract2012;2012:489135.
SankaralingamSKimRBPadwalRS. The impact of obesity on the pharmacology of medications used for cardiovascular risk factor control. Can J Cardiol2015;31:167–176.
VelissarisDKaramouzosVMarangosM. Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review. J Clin Med Res2014;6:227–233.
Al-DorziHMAl HarbiSAArabiYM. Antibiotic therapy of pneumonia in the obese patient: dosing and delivery. Curr Opin Infect Dis2014;27:165–173.
HallRG2ndJeanGWSiglerMShahS. Dosing considerations for obese patients receiving cancer chemotherapeutic agents. Ann Pharmacother2013;47:1666–1674.
GriggsJJManguPBAndersonH. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol2012;30:1553–1561.
AgnelliGBergqvistDCohenAT. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg2005;92:1212–1220.
FrederiksenSGHedenbroJLNorgrenL. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg2003;90:547–548.
KucherNLeizoroviczAVaitkusPT. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med2005;165:341–345.
BickfordAMajercikSBledsoeJ. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. Am J Surg2013;206:847–851discussion 851–842.
RaftopoulosIMartindaleCCroninASteinbergJ. The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial. Surg Endosc2008;22:2384–2391.
WangTFMilliganPEWongCA. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost2014;111:88–93.
IkesakaRDellucALe GalGCarrierM. Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. Thromb Res2014;133:682–687.
VandiverJWRitzLILalamaJT. Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations[published online ahead of print May 17 2015]. J Thromb Thrombolysisin press.
MageeCJBarryJJavedS. Extended thromboprophylaxis reduces incidence of postoperative venous thromboembolism in laparoscopic bariatric surgery. Surg Obes Relat Dis2010;6:322–325.
SimoneauMDVachonAPicardF. Effect of prophylactic dalteparin on anti-factor Xa levels in morbidly obese patients after bariatric surgery. Obes Surg2010;20:487–491.
ScholtenDJHoedemaRMScholtenSE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg2002;12:19–24.
HamadGGChobanPS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg2005;15:1368–1374.
SimoneEPMadanAKTichanskyDS. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc2008;22:2392–2395.
SteeleKECannerJProkopowiczG. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surg Obes Relat Dis2015;11:672–683.
CelikFHuitemaADHooijbergJH. Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-xa levels. Obes Surg2015;25:628–634.
RondinaMTWheelerMRodgersGM. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res2010;125:220–223.
LudwigKPSimonsHJMoneM. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. Ann Pharmacother2011;45:1356–1362.
FreemanAHornerTPendletonRCRondinaMT. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol2012;87:740–743.
SinghKPodolskyERUmS. Evaluating the safety and efficacy of BMI-based preoperative administration of low-molecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg2012;22:47–51.
Borkgren-OkonekMJHartRWPantanoJE. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis2008;4:625–631.
BecattiniCAgnelliGManinaG. Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. Surg Obes Relat Dis2012;8:108–115.
StrohCBirkDFlade-KutheR. Evidence of thromboembolism prophylaxis in bariatric surgery-results of a quality assurance trial in bariatric surgery in Germany from 2005 to 2007 and review of the literature. Obes Surg2009;19:928–936.
MillerMTRovitoPF. An approach to venous thromboembolism prophylaxis in laparoscopic Roux-en-Y gastric bypass surgery. Obes Surg2004;14:731–737.
TurpieAGBauerKAErikssonBILassenMR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med2002;162:1833–1840.
MartinezLBurnettABorregoM. Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity. Am J Health Syst Pharm2011;68:1716–1722.
LinBShaoLLuoQ. Prevalence of chronic kidney disease and its association with metabolic diseases: a cross-sectional survey in Zhejiang province, Eastern China. BMC Nephrol2014;15:36.
KhajehdehiPMalekmakanLPakfetratM. Prevalence of chronic kidney disease and its contributing risk factors in southern Iran: a cross-sectional adult population-based study. Iran J Kidney Dis2014;8:109–115.
TsujimotoTSairenchiTIsoH. The dose-response relationship between body mass index and the risk of incident stage >/=3 chronic kidney disease in a general japanese population: the Ibaraki prefectural health study (IPHS). J Epidemiol2014;24:444–451.
CookLMKahnSRGoodwinJKovacsMJ. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost2007;5:937–941.
NutescuEASpinlerSAWittkowskyADagerWE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother2009;43:1064–1083.
DealENHollandsJMRineyJN. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series. J Thromb Thrombolysis2011;32:188–194.
GerlachATPickworthKKSethSK. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy2000;20:771–775.
HoffmannPKellerF. Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis. Eur J Clin Pharmacol2012;68:757–765.
KothariSNLambertPJMathiasonMA. Best Poster Award. A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin. Am J Surg2007;194:709–711.
BrasileiroALMirandaFJrEttingerJE. Incidence of lower limbs deep vein thrombosis after open and laparoscopic gastric bypass: a prospective study. Obes Surg2008;18:52–57.
KhoursheedMAl-BaderIAl-AsfarF. Therapeutic effect of low-molecular weight heparin and incidence of lower limb deep venous thrombosis and pulmonary embolism after laparoscopic bariatric surgery. Surg Laparosc Endosc Percutan Tech2013;23:491–493.
Escalante-TattersfieldTTuckerOFajnwaksP. Incidence of deep vein thrombosis in morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis2008;4:126–130.
PrystowskyJBMoraschMDEskandariMK. Prospective analysis of the incidence of deep venous thrombosis in bariatric surgery patients. Surgery2005;138:759–763; discussion 763–755.
McCulloughPAGallagherMJDejongAT. Cardiorespiratory fitness and short-term complications after bariatric surgery. Chest2006;130:517–525.
VaziriKBhanotPHungnessES. Retrievable inferior vena cava filters in high-risk patients undergoing bariatric surgery. Surg Endosc2009;23:2203–2207.